Literature DB >> 24821346

A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.

Michael I Fingerhood1, Van L King, Robert K Brooner, Darius A Rastegar.   

Abstract

BACKGROUND: The purpose of this study was to compare demographic factors and 1-year treatment outcomes of patients treated with buprenorphine or methadone.
METHODS: The study included 252 subjects who received a prescription for buprenorphine in an academic internal medicine practice and 252 subjects who enrolled in a methadone maintenance program located on the same campus over the same time frame. Data were collected retrospectively. Patients were classified as "opioid-positive" or "opioid-negative" each month for a year based on urine drug testing and provider assessment. Successful treatment was defined as remaining in treatment after 1 year and achieving 6 or more opioid-negative months.
RESULTS: Buprenorphine patients were more likely to be male, have health insurance, be employed, abuse prescription opioids, and be human immunodeficiency virus (HIV) infected; they were less likely to abuse benzodiazepines. At 12 months, 140 (55.6%) of buprenorphine patients and 156 (61.9%) of methadone patients remained in treatment (P =.148). Patients on methadone had a higher mean number of opioid-negative months (6.96 vs. 5.43; P <.001) and mean number of months in treatment (9.38 vs. 8.59; P <.001). On multivariable analysis, methadone maintenance was significantly associated with successful treatment (adjusted odds ratio: 2.10; 95% confidence interval: 1.43-3.07).
CONCLUSIONS: Office-based buprenorphine and methadone maintenance programs serve very different populations. Both are effective, but patients on methadone had mildly better treatment outcomes.

Entities:  

Keywords:  Buprenorphine, methadone, opioid-dependent, treatment

Mesh:

Substances:

Year:  2014        PMID: 24821346     DOI: 10.1080/08897077.2013.819828

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  19 in total

1.  Prescription opioid use patterns, use disorder diagnoses and addiction treatment receipt after the 2014 Medicaid expansion in Oregon.

Authors:  Rachel Springer; Miguel Marino; Steffani R Bailey; Heather Angier; Jean P O'Malley; Megan Hoopes; Stephan Lindner; Jennifer E DeVoe; Nathalie Huguet
Journal:  Addiction       Date:  2019-06-30       Impact factor: 6.526

2.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

3.  Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.

Authors:  Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Eric C Strain
Journal:  Addict Behav       Date:  2017-07-14       Impact factor: 3.913

4.  Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients.

Authors:  Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Michael Fingerhood; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2015-10-19       Impact factor: 4.492

Review 5.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Authors:  Kathleen M Carroll; Roger D Weiss
Journal:  Am J Psychiatry       Date:  2016-12-16       Impact factor: 18.112

6.  Long-term retention in Office Based Opioid Treatment with buprenorphine.

Authors:  Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2016-12-30

7.  Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.

Authors:  Katelyn J Carey; Wei Huang; Benjamin P Linas; Judith I Tsui
Journal:  J Subst Abuse Treat       Date:  2016-02-13

8.  Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs.

Authors:  Fabio Lugoboni; Frances Rudnick Levin; Maria Chiara Pieri; Matteo Manfredini; Lorenzo Zamboni; Lorenzo Somaini; Gilberto Gerra
Journal:  Psychiatry Res       Date:  2017-01-21       Impact factor: 3.222

9.  E-cigarette knowledge, attitudes, and use in opioid dependent smokers.

Authors:  Michael D Stein; Celeste M Caviness; Kristin Grimone; Daniel Audet; Allison Borges; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2014-11-20

10.  Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.

Authors:  Elizabeth A Evans; Caroline Yoo; David Huang; Andrew J Saxon; Yih-Ing Hser
Journal:  J Subst Abuse Treat       Date:  2019-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.